3-(β-D-glucopyranosyloxy)-5-methyl-4-{[4-(cyclopropylidene-methyl)phenyl]methyl}-1H-pyrazole

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(β-D-glucopyranosyloxy)-5-methyl-4-{[4-(cyclopropylidene-methyl)phenyl]methyl}-1H-pyrazole
• 英文别名: 3-(beta-D-glucopyranosyloxy)-5-methyl-4-{[4-(cyclopropylidenemethyl)phenyl]methyl}-1H-pyrazole；(2S,3R,4S,5S,6R)-2-[[4-[[4-(cyclopropylidenemethyl)phenyl]methyl]-5-methyl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₁H₂₆N₂O₆
• 分子量: 402.447
• InChiKey: MYVKFHBYTFOCKI-YRIDSSQKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  128
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl 4-(cyclopropylidenemethyl)benzoate 在 甲醇 、 lithium aluminium tetrahydride 、 sodium methylate 、 sodium hydride 、 三乙胺 、 silver carbonate 、 肼 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 甲苯 为溶剂， 反应 83.17h， 生成 3-(β-D-glucopyranosyloxy)-5-methyl-4-{[4-(cyclopropylidene-methyl)phenyl]methyl}-1H-pyrazole
  参考文献：
  名称：

  GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1364957B1

文献信息

• Glucopyranosyloxypyrazole derivatives and medicinal use thereof
  申请人：Nishimura Toshihiro

  公开号：US20060142209A1

  公开（公告）日：2006-06-29

  The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R 1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R 2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

  本发明提供一种由下式表示的葡萄糖吡唑衍生物：其中Q和T中的一个表示由下式表示的基团：而另一个表示较低的烷基或卤代（较低的烷基）基团；R1表示氢原子、可选地取代的较低烷基基团、较低烯基基团、环状较低烷基基团等；R2表示氢原子、可选地取代的较低烷基基团、较低烷氧基基团、较低烯基基团、环状较低烷基基团、环状较低烷氧基基团等，这些化合物在人类SGLT2中表现出优异的抑制活性，因此可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，其药学上可接受的盐或前药，其生产中间体以及其制药用途。
• Glycopyranosyloxypyrazole derivatives and medicinal use thereof
  申请人：——

  公开号：US20040132669A1

  公开（公告）日：2004-07-08

  The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: 1 wherein one of Q and T represents a group represented by the general formula: 2 while the other represents a lower alkyl group or a halo(lower alkyl) group; R 1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R 2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

  本发明提供了一种由通式1表示的葡萄糖吡唑衍生物，其中Q和T中的一个表示由通式2表示的基团，而另一个表示较低的烷基基团或卤代（较低的烷基）基团；R1表示氢原子、可选取代的较低烷基基团、较低烯基基团、环状较低烷基基团等；R2表示氢原子、可选取代的较低烷基基团、较低烷氧基团、较低烯基基团、环状较低烷基基团、环状较低烷氧基团等。这些衍生物在人类SGLT2中具有出色的抑制活性，因此可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及其药学上可接受的盐或前药、生产中间体及其制药用途。
• Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
  申请人：Katsuno Kenji

  公开号：US20080045466A1

  公开（公告）日：2008-02-21

  The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.
• PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT
  申请人：KATSUNO Kenji

  公开号：US20090286751A1

  公开（公告）日：2009-11-19

  The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcoholic fatty liver disease toxic fatty liver or the like.
• US7087579B2
  申请人：——

  公开号：US7087579B2

  公开（公告）日：2006-08-08